CN113679722A - Compositions and methods for treating neovascularized skin disorders - Google Patents
Compositions and methods for treating neovascularized skin disorders Download PDFInfo
- Publication number
- CN113679722A CN113679722A CN202111133802.6A CN202111133802A CN113679722A CN 113679722 A CN113679722 A CN 113679722A CN 202111133802 A CN202111133802 A CN 202111133802A CN 113679722 A CN113679722 A CN 113679722A
- Authority
- CN
- China
- Prior art keywords
- skin
- neovascularized
- treating
- caused
- nintedanib
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Withdrawn
Links
- 208000017520 skin disease Diseases 0.000 title claims abstract description 39
- 238000000034 method Methods 0.000 title claims abstract description 21
- 239000000203 mixture Substances 0.000 title abstract description 5
- XZXHXSATPCNXJR-ZIADKAODSA-N nintedanib Chemical compound O=C1NC2=CC(C(=O)OC)=CC=C2\C1=C(C=1C=CC=CC=1)\NC(C=C1)=CC=C1N(C)C(=O)CN1CCN(C)CC1 XZXHXSATPCNXJR-ZIADKAODSA-N 0.000 claims abstract description 28
- 229960004378 nintedanib Drugs 0.000 claims abstract description 28
- 206010029113 Neovascularisation Diseases 0.000 claims abstract description 19
- 239000003814 drug Substances 0.000 claims description 8
- 239000000463 material Substances 0.000 claims description 6
- 208000010201 Exanthema Diseases 0.000 claims description 3
- 230000000172 allergic effect Effects 0.000 claims description 3
- 208000010668 atopic eczema Diseases 0.000 claims description 3
- 230000001580 bacterial effect Effects 0.000 claims description 3
- 201000005884 exanthem Diseases 0.000 claims description 3
- 230000002538 fungal effect Effects 0.000 claims description 3
- 230000035876 healing Effects 0.000 claims description 3
- 238000002347 injection Methods 0.000 claims description 3
- 239000007924 injection Substances 0.000 claims description 3
- 238000002360 preparation method Methods 0.000 claims description 3
- 206010037844 rash Diseases 0.000 claims description 3
- 208000035143 Bacterial infection Diseases 0.000 claims description 2
- 201000004624 Dermatitis Diseases 0.000 claims description 2
- 206010017533 Fungal infection Diseases 0.000 claims description 2
- 206010020649 Hyperkeratosis Diseases 0.000 claims description 2
- 206010020843 Hyperthermia Diseases 0.000 claims description 2
- 208000031888 Mycoses Diseases 0.000 claims description 2
- 208000030852 Parasitic disease Diseases 0.000 claims description 2
- 201000004681 Psoriasis Diseases 0.000 claims description 2
- 206010039203 Road traffic accident Diseases 0.000 claims description 2
- 206010039710 Scleroderma Diseases 0.000 claims description 2
- 208000036142 Viral infection Diseases 0.000 claims description 2
- 208000027418 Wounds and injury Diseases 0.000 claims description 2
- 230000005856 abnormality Effects 0.000 claims description 2
- 208000022362 bacterial infectious disease Diseases 0.000 claims description 2
- 239000000839 emulsion Substances 0.000 claims description 2
- 230000036031 hyperthermia Effects 0.000 claims description 2
- 208000014674 injury Diseases 0.000 claims description 2
- 239000007788 liquid Substances 0.000 claims description 2
- 238000001356 surgical procedure Methods 0.000 claims description 2
- 230000008733 trauma Effects 0.000 claims description 2
- 230000003612 virological effect Effects 0.000 claims description 2
- 239000003795 chemical substances by application Substances 0.000 claims 4
- 206010067248 Congenital naevus Diseases 0.000 claims 2
- 239000012678 infectious agent Substances 0.000 claims 2
- 206010004146 Basal cell carcinoma Diseases 0.000 claims 1
- 201000011066 hemangioma Diseases 0.000 claims 1
- 230000002757 inflammatory effect Effects 0.000 claims 1
- 239000007972 injectable composition Substances 0.000 claims 1
- 239000008177 pharmaceutical agent Substances 0.000 claims 1
- 239000000049 pigment Substances 0.000 claims 1
- 230000000699 topical effect Effects 0.000 claims 1
- DNIAPMSPPWPWGF-UHFFFAOYSA-N Propylene glycol Chemical compound CC(O)CO DNIAPMSPPWPWGF-UHFFFAOYSA-N 0.000 description 9
- 241000700159 Rattus Species 0.000 description 6
- 230000033115 angiogenesis Effects 0.000 description 4
- 206010002198 Anaphylactic reaction Diseases 0.000 description 3
- 230000007059 acute toxicity Effects 0.000 description 3
- 231100000403 acute toxicity Toxicity 0.000 description 3
- 239000002671 adjuvant Substances 0.000 description 3
- 208000003455 anaphylaxis Diseases 0.000 description 3
- 239000003153 chemical reaction reagent Substances 0.000 description 3
- 230000007794 irritation Effects 0.000 description 3
- 229940100611 topical cream Drugs 0.000 description 3
- 229940100615 topical ointment Drugs 0.000 description 3
- 239000003871 white petrolatum Substances 0.000 description 3
- 108091008794 FGF receptors Proteins 0.000 description 2
- 102000044168 Fibroblast Growth Factor Receptor Human genes 0.000 description 2
- 201000009794 Idiopathic Pulmonary Fibrosis Diseases 0.000 description 2
- 108091008606 PDGF receptors Proteins 0.000 description 2
- 102000011653 Platelet-Derived Growth Factor Receptors Human genes 0.000 description 2
- 108091008605 VEGF receptors Proteins 0.000 description 2
- 102000009484 Vascular Endothelial Growth Factor Receptors Human genes 0.000 description 2
- 208000036971 interstitial lung disease 2 Diseases 0.000 description 2
- 208000002154 non-small cell lung carcinoma Diseases 0.000 description 2
- 238000011084 recovery Methods 0.000 description 2
- 208000029729 tumor suppressor gene on chromosome 11 Diseases 0.000 description 2
- 229940124676 vascular endothelial growth factor receptor Drugs 0.000 description 2
- VEEGZPWAAPPXRB-BJMVGYQFSA-N (3e)-3-(1h-imidazol-5-ylmethylidene)-1h-indol-2-one Chemical compound O=C1NC2=CC=CC=C2\C1=C/C1=CN=CN1 VEEGZPWAAPPXRB-BJMVGYQFSA-N 0.000 description 1
- 208000015898 Bacterial Skin disease Diseases 0.000 description 1
- 206010012504 Dermatophytosis Diseases 0.000 description 1
- 241001465754 Metazoa Species 0.000 description 1
- ZDZOTLJHXYCWBA-VCVYQWHSSA-N N-debenzoyl-N-(tert-butoxycarbonyl)-10-deacetyltaxol Chemical compound O([C@H]1[C@H]2[C@@](C([C@H](O)C3=C(C)[C@@H](OC(=O)[C@H](O)[C@@H](NC(=O)OC(C)(C)C)C=4C=CC=CC=4)C[C@]1(O)C3(C)C)=O)(C)[C@@H](O)C[C@H]1OC[C@]12OC(=O)C)C(=O)C1=CC=CC=C1 ZDZOTLJHXYCWBA-VCVYQWHSSA-N 0.000 description 1
- 208000006981 Skin Abnormalities Diseases 0.000 description 1
- 208000009956 adenocarcinoma Diseases 0.000 description 1
- 229940121369 angiogenesis inhibitor Drugs 0.000 description 1
- 239000004037 angiogenesis inhibitor Substances 0.000 description 1
- 230000009286 beneficial effect Effects 0.000 description 1
- 239000003181 biological factor Substances 0.000 description 1
- 230000015572 biosynthetic process Effects 0.000 description 1
- 201000010099 disease Diseases 0.000 description 1
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 1
- 229960003668 docetaxel Drugs 0.000 description 1
- 229940079593 drug Drugs 0.000 description 1
- 230000000694 effects Effects 0.000 description 1
- 230000002124 endocrine Effects 0.000 description 1
- 238000002474 experimental method Methods 0.000 description 1
- 238000011354 first-line chemotherapy Methods 0.000 description 1
- 230000002068 genetic effect Effects 0.000 description 1
- 229940088592 immunologic factor Drugs 0.000 description 1
- 239000000367 immunologic factor Substances 0.000 description 1
- 208000015181 infectious disease Diseases 0.000 description 1
- 208000012929 large congenital melanocytic nevus Diseases 0.000 description 1
- 230000004060 metabolic process Effects 0.000 description 1
- 230000001394 metastastic effect Effects 0.000 description 1
- 206010061289 metastatic neoplasm Diseases 0.000 description 1
- 238000012986 modification Methods 0.000 description 1
- 230000004048 modification Effects 0.000 description 1
- 102000005962 receptors Human genes 0.000 description 1
- 108020003175 receptors Proteins 0.000 description 1
- 230000000306 recurrent effect Effects 0.000 description 1
- 208000020352 skin basal cell carcinoma Diseases 0.000 description 1
- 201000009381 skin hemangioma Diseases 0.000 description 1
- 231100000046 skin rash Toxicity 0.000 description 1
- 239000000243 solution Substances 0.000 description 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/496—Non-condensed piperazines containing further heterocyclic rings, e.g. rifampin, thiothixene or sparfloxacin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0012—Galenical forms characterised by the site of application
- A61K9/0014—Skin, i.e. galenical aspects of topical compositions
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0012—Galenical forms characterised by the site of application
- A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
- A61P17/02—Drugs for dermatological disorders for treating wounds, ulcers, burns, scars, keloids, or the like
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
- A61P17/06—Antipsoriatics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/04—Antibacterial agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/10—Antimycotics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P33/00—Antiparasitic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/08—Antiallergic agents
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- Chemical & Material Sciences (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Organic Chemistry (AREA)
- Dermatology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Engineering & Computer Science (AREA)
- Immunology (AREA)
- Epidemiology (AREA)
- Communicable Diseases (AREA)
- Oncology (AREA)
- Pulmonology (AREA)
- Virology (AREA)
- Pain & Pain Management (AREA)
- Rheumatology (AREA)
- Tropical Medicine & Parasitology (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Abstract
The invention discloses a composition and a method for treating skin diseases caused by neovascularization by nintedanib. The application of the nintedanib in the clinical treatment of the skin diseases caused by the neovascularization can help the patients to recover as soon as possible, and the skin is kept as the original as possible.
Description
Technical Field
The invention relates to the technical field of medicines, in particular to a composition and a method for treating skin diseases caused by neovascularization by nintedanib.
Background
Nintedanib is a novel angiogenesis inhibitor and can simultaneously act on 3 key receptor families involved in the angiogenesis process: vascular Endothelial Growth Factor Receptor (VEGFR), Platelet Derived Growth Factor Receptor (PDGFR) and Fibroblast Growth Factor Receptor (FGFR). Nintedanib has been approved by FDA and EMA for the marketing of treatment of Idiopathic Pulmonary Fibrosis (IPF), and also by EMA in combination with docetaxel for use in adult patients with locally advanced or metastatic or locally recurrent non-small cell lung cancer (NSCLC) who have been histologically diagnosed as adenocarcinoma after first-line chemotherapy. A plurality of existing skin diseases are related to angiogenesis to cause local skin abnormality, but the existing products can not solve the problems brought by angiogenesis in the treatment process, and no method for treating the skin diseases formed by angiogenesis by adopting nintedanib is adopted at present.
Disclosure of Invention
In view of the above, the present invention aims to provide a composition and a method for treating a skin disease caused by neovascularization by nintedanib, so as to solve the problems of the prior art.
The method for treating the skin diseases caused by neovascularization by the nintedanib comprises the step of preparing a medicament by adding auxiliary materials into the nintedanib, and the medicament can accelerate the healing and recovery of the skin diseases by local administration.
Further, the neovascularized skin disease is a neovascularization induced by viral, bacterial, fungal or parasitic infection, trauma, traffic accident, surgery, hyperthermia, genetics.
Furthermore, the skin diseases caused by the neovascularization are inflammatory skin diseases caused by infection factors, skin rash caused by allergic factors, color spots caused by immune factors, congenital pigmented nevus, skin keratosis, hemangioma, basal cell carcinoma and skin diseases caused by wound abnormality.
Further, the skin diseases of neovascularization are genetic, food and other diseases, biological factors, metabolism and endocrine factor formation.
Further, the skin disease of neovascularization is psoriasis.
Further, the neovascularized skin disease is scleroderma.
Further, the skin disease of neovascularization is a fungal skin disease.
Further, the neovascularisation skin disease is a bacterial skin disease.
Further, the administration may be by injection or external application.
Further, the medicament is one of an injection preparation and an external preparation such as a liquid, an emulsion and the like.
By adopting the technical scheme, the method has the following beneficial effects:
the application of the nintedanib in the clinical treatment of the skin diseases caused by the neovascularization can help the patients to recover as soon as possible, and the skin is kept as the original as possible.
Detailed Description
The technical solution of the present invention is described in more detail and fully below.
Example 1: the invention aims to provide a new application of nintedanib, and the following further experiments are carried out on treatment of animal experimental models.
Test materials: 100 SD rats with a skin disease of neovascularization;
reagent: 99.97% pure nintedanib);
adding adjuvants into Nintedanib to make into topical ointment, such as 1 part of Nintedanib, 10 parts of white vaseline, and 10 parts of propylene glycol, and mixing to obtain Nintedanib topical cream. The product has no obvious acute toxicity reaction, no irritation, and no local or systemic anaphylaxis when being applied to rat skin.
Example 2: test materials: 100 SD rats with a skin disease of neovascularization;
reagent: 99.97% pure nintedanib);
adding adjuvants into Nintedanib to make into topical ointment, such as 10 parts of Nintedanib, 10 parts of white vaseline, and 10 parts of propylene glycol, and mixing to obtain Nintedanib topical cream. The product has no obvious acute toxicity reaction, no irritation, and no local or systemic anaphylaxis when being applied to rat skin.
Example 3: test materials: 100 SD rats with a skin disease of neovascularization;
reagent: 99.97% pure nintedanib);
adding adjuvants into Nintedanib to make into topical ointment, such as Nintedanib 30 parts, white vaseline 10 parts, and propylene glycol 10 parts, and mixing to obtain Nintedanib topical cream. The product has no obvious acute toxicity reaction, no irritation, and no local or systemic anaphylaxis when being applied to rat skin.
| Days of treatment | Example 1 (% treatment) | Example 2 (% treatment) | Example 2 (% treatment) |
| 10 days | 10 | 20 | 30 |
| 20 days | 20 | 40 | 70 |
| 30 days | 40 | 60 | 90 |
According to the results, the following results are shown: the nintedanib has good treatment effect on the skin diseases caused by neovascularization.
Therefore, the method for treating the skin diseases caused by neovascularization by the nintedanib comprises the step of preparing the nintedanib into a medicament by adding auxiliary materials, and the medicament is locally administered to accelerate the healing and recovery of the skin diseases.
Having thus described the basic principles and principal features of the invention, it will be appreciated by those skilled in the art that the invention is not limited by the embodiments described above, which are given by way of illustration only, but that various changes and modifications may be made therein without departing from the spirit and scope of the invention as defined by the appended claims and their equivalents.
Claims (10)
1. The method for treating the skin diseases caused by neovascularization by the nintedanib is characterized by comprising the step of preparing a medicament by adding auxiliary materials into the nintedanib, wherein the medicament can accelerate healing of the skin diseases and recover to normal by local administration.
2. The method of treating neovascularized skin disease of claim 1, wherein said neovascularized skin disease is neovascularization induced by viral, bacterial, fungal or parasitic infection, trauma, automobile accident, surgery, hyperthermia, genetics.
3. The method of claim 1, wherein the neovascularized skin disease is an inflammatory skin disease caused by an infectious agent, a rash caused by an allergic agent, a stain caused by an immune agent, a congenital nevus pigmentosus, a skin keratosis, a hemangioma, a basal cell carcinoma, a skin disease caused by wound abnormalities.
4. The method of treating a neovascularized skin disorder according to claim 1, wherein the neovascularized skin disorder is psoriasis.
5. The method of treating a neovascularized skin disorder according to claim 1, wherein the neovascularized skin disorder is scleroderma.
6. The method of treating a neovascularized skin disorder according to claim 1, wherein the neovascularized skin disorder is a fungal skin disorder.
7. The method of treating a neovascularized skin condition of claim 1, wherein the neovascularized skin condition is a bacterial skin condition.
8. The method of claim 1, wherein said administering is by injection or by topical application.
9. The method for treating a neovascular skin disease as set forth in claim 1, wherein the pharmaceutical agent is one of an injectable formulation and an external preparation such as a liquid, an emulsion, etc.
10. The method of claim 1, wherein the neovascularized skin condition is an inflammatory skin condition caused by an infectious agent, a rash caused by an allergic agent, a stain caused by an immune agent, a congenital nevus pigment.
Priority Applications (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN202111133802.6A CN113679722A (en) | 2021-09-27 | 2021-09-27 | Compositions and methods for treating neovascularized skin disorders |
| PCT/CN2022/118928 WO2023045818A1 (en) | 2021-09-27 | 2022-09-15 | Composition of nintedanib for treating skin diseases formed by neovascularization, and method |
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN202111133802.6A CN113679722A (en) | 2021-09-27 | 2021-09-27 | Compositions and methods for treating neovascularized skin disorders |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| CN113679722A true CN113679722A (en) | 2021-11-23 |
Family
ID=78587224
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CN202111133802.6A Withdrawn CN113679722A (en) | 2021-09-27 | 2021-09-27 | Compositions and methods for treating neovascularized skin disorders |
Country Status (2)
| Country | Link |
|---|---|
| CN (1) | CN113679722A (en) |
| WO (1) | WO2023045818A1 (en) |
Cited By (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO2023045818A1 (en) * | 2021-09-27 | 2023-03-30 | 张国华 | Composition of nintedanib for treating skin diseases formed by neovascularization, and method |
Family Cites Families (7)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US10736885B2 (en) * | 2015-10-07 | 2020-08-11 | Aiviva Biopharma, Inc. | Compositions and methods of treating dermal fibrotic disorders |
| US20190388407A1 (en) * | 2017-02-12 | 2019-12-26 | Aiviva Biopharma, Inc. | Multikinase inhibitors of vegf and tfg beta and uses thereof |
| CN107028949A (en) * | 2017-05-25 | 2017-08-11 | 瑞阳制药有限公司 | Nintedanib is used to treat the purposes in the external preparation medicine of psoriasis |
| EP3650040A1 (en) * | 2018-11-07 | 2020-05-13 | Galderma Research & Development | Vegf inhibitors for use for preventing and/or treating atopic dermatitis |
| CN113384570B (en) * | 2021-07-13 | 2022-08-26 | 山东省妇幼保健院 | Application of caffeic acid methyl ester and triazole composition in preparation of antifungal products |
| CN113679722A (en) * | 2021-09-27 | 2021-11-23 | 张国华 | Compositions and methods for treating neovascularized skin disorders |
| CN114392261A (en) * | 2022-01-18 | 2022-04-26 | 张国华 | Compositions and methods for treating neovascularized skin disorders |
-
2021
- 2021-09-27 CN CN202111133802.6A patent/CN113679722A/en not_active Withdrawn
-
2022
- 2022-09-15 WO PCT/CN2022/118928 patent/WO2023045818A1/en unknown
Cited By (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO2023045818A1 (en) * | 2021-09-27 | 2023-03-30 | 张国华 | Composition of nintedanib for treating skin diseases formed by neovascularization, and method |
Also Published As
| Publication number | Publication date |
|---|---|
| WO2023045818A1 (en) | 2023-03-30 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| DE69434490T2 (en) | Compilations for cancer treatment | |
| EP0694307B1 (en) | Atopic disease remedy | |
| KR20170010442A (en) | Compositions containing berberine or analogs thereof for treating rosacea or red face related skin disorders | |
| CN104323995A (en) | Cefpiramide sodium lipidosome combined drug, and large-scale production technology and application thereof | |
| Bakhshi et al. | Combination therapy with 1% nanocurcumin gel and 0.1% triamcinolone acetonide mouth rinse for oral lichen planus: A randomized double-blind placebo controlled clinical trial | |
| CN113679722A (en) | Compositions and methods for treating neovascularized skin disorders | |
| CN114392261A (en) | Compositions and methods for treating neovascularized skin disorders | |
| CN103127140B (en) | Compound external use drug curing psoriasis | |
| CN113041210B (en) | Colchicine external composition | |
| EP0263417A1 (en) | Use of hyaluronidase | |
| CN101912364B (en) | Ginkgolide B liposome medicinal composition | |
| US20100323998A1 (en) | Topical composition containing the combination of mupirocin and beclomethasone | |
| JP2000095683A (en) | Skin lotion | |
| CN104869994B (en) | Pidotimod treats psoriatic purposes | |
| KR102526210B1 (en) | Composition for improving skin regeneration and wound-healing comprising fermented Mastic Gum extract and method for manufacturing the same | |
| CN113876777A (en) | Method for treating osteoarticular diseases caused by abnormal neovascularization by Nintedanib | |
| CN107205974A (en) | A kind of sulfonamide drug composition | |
| CN101766614A (en) | Omeprazole sodium combined medicament and preparation method thereof | |
| CN110327284A (en) | A kind of cefodizime sodium for injection and preparation method thereof | |
| FI85945B (en) | FOERFARANDE FOER FRAMSTAELLNING AV EN PRODUKT AVSEDD FOER SKOETSEL AV SJUKDOMEN PSORIASIS. | |
| DE102010009071A1 (en) | Preparing edible film useful for oral bioactivator, involves dissolving polyethylene glycol and sugar in water, and adding and mixing glycerol with polyethylene glycol-sugar solution | |
| CN110101709B (en) | Compound camphor emulsifiable paste and preparation method thereof | |
| US20230414558A1 (en) | Plectranthus amboinicus extract for use in alleviation of radiation-induced skin disorders | |
| CN114377079B (en) | Traditional Chinese medicine skin-moistening composition and preparation method and application thereof | |
| US20240122949A1 (en) | Method of treating various disorders and conditions using citicoline |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| PB01 | Publication | ||
| PB01 | Publication | ||
| SE01 | Entry into force of request for substantive examination | ||
| SE01 | Entry into force of request for substantive examination | ||
| WW01 | Invention patent application withdrawn after publication |
Application publication date: 20211123 |
|
| WW01 | Invention patent application withdrawn after publication |